ACS Nano · 2024 · 96 citations · 22 references
Life SciencesNeurobiologyNeuroscienceDrug DeliveryInflammationNeuroimmunologyAcute Ischemic StrokeBlood-brain Barrier DeliveryBrain Targeted DeliveryNeuroinflammationNeuroprotectionStrokeBlood-brain Barrier PermeabilityLipid Nanoparticle DeliveryMicroglia ModulationMicroglia-blood-brain Barrier InteractionsMicroglial PolarizationNeuroinflammation In StrokeNeuroinflammation ModulationStroke Neuroprotection
The ischemic stroke is a major global health concern, with high mortality and disability rates. Unfortunately, there is a dearth of effective clinical interventions for managing poststroke neuroinflammation and blood–brain barrier (BBB) disruption that are crucial for the brain injury evolving and neurological deficits. By leveraging the pathological progression of an ischemic stroke, we developed an M2 microglia-targeting lipid nanoparticle (termed MLNP) approach that can selectively deliver mRNA encoding phenotype-switching interleukin-10 (m IL-10 ) to the ischemic brain, creating a beneficial feedback loop that drives microglial polarization toward the protective M2 phenotypes and augments the homing of m IL-10 -loaded MLNPs (m IL-10 @MLNPs) to ischemic regions. In a transient middle cerebral artery occlusion (MCAO) mouse model of an ischemic stroke, our findings demonstrate that intravenously injected m IL-10 @MLNPs induce IL-10 production and enhance the M2 polarization of microglia. The resulting positive loop reinforces the resolution of neuroinflammation, restores the impaired BBB, and prevents neuronal apoptosis after stroke. Using a permanent distal MCAO mouse model of an ischemic stroke, the neuroprotective effects of m IL-10 @MLNPs have been further validated by the attenuation of the sensorimotor and cognitive neurological deficits. Furthermore, the developed mRNA-based targeted therapy has great potential to extend the therapeutic time window at least up to 72 h poststroke. This study depicts a simple and versatile LNP platform for selective delivery of mRNA therapeutics to cerebral lesions, showcasing a promising approach for addressing an ischemic stroke and associated brain conditions.
22
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist et al. · Nature · 2020 · 1.7K citations · Full text
CAR T cells produced in vivo to treat cardiac injury
Restoring metabolism of myeloid cells reverses cognitive decline in ageing
Paras S. Minhas, Amira Latif‐Hernandez, Melanie R. McReynolds et al. · Nature · 2021 · 521 citations · Full text